Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type
TheraVet SA EU:ALVET Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30 -7.41% 3.75 3.56 4.00 4.00 3.60 4.00 7,055 02:00:52

TheraVet: Commercial launch of BIOCERA-VET® in France and The Netherlands

21/10/2021 6:30am

Business Wire


TheraVet (EU:ALVET)
Historical Stock Chart


From Sep 2021 to Sep 2022

Click Here for more TheraVet Charts.
  • Commercial launch of BIOCERA-VET® in France and The Netherlands as planned
  • First sales registered in those countries

Regulatory News:

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in companion animals, announces today the commercial launch of BIOCERA-VET® - Bone Surgery in France and The Netherlands.

After the successful launch of BIOCERA-VET® in Belgium earlier this year, TheraVet is pursuing its European commercial expansion strategy with the launch, as planned, in France and in The Netherlands. TheraVet has already registered its first sales in those countries.

With this new step, TheraVet enters a market of more than 25 million of companions (dogs and cats). France alone, with 22 million dogs and cats1, is the second largest pet market in Europe.

Enrico Bastianelli, Chief Executive Officer of TheraVet, concludes: “We are delighted to achieve the first sales of BIOCERA-VET® in France and in The Netherlands, marking the start of commercialization in those countries. These launches, especially in France, the second most important orthopedic market in Europe, are important commercial milestones .”

About TheraVet SA TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from osteoarticular diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris et Brussels, its head office is in Gosselies, Belgium, and it has a subsidiary in the US. For more information, visit the TheraVet website Or follow us on LinkedIn / Facebook / Twitter

1 The European Pet Food Industry, Fediaf, Annual Report 2020

TheraVet Sabrina Ena Chief Operating Officer sabrina.ena@thera.vet

Julie Winand Chief Corporate Officer julie.winand@thera.vet

NewCap Investor Relations and Financial Communications Louis Tilquin / Olivier Bricaud theravet@newcap.eu Tel: +33 (0)1 44 71 94 94

Press Relations Arthur Rouillé / Ambre Delval theravet@newcap.eu Tel: +33 (0)1 44 71 00 15

1 Year TheraVet Chart

1 Year TheraVet Chart

1 Month TheraVet Chart

1 Month TheraVet Chart
ADVFN Advertorial
Your Recent History
EU
ALVET
TheraVet
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220927 05:02:05